Intersect ENT (NSDQ:XENT) announced today that it received CE mark approval for its Propel Contour sinus implant.
Menlo Park, Calif.-based Intersect ENT designed its Propel Contour sinus implant to maintain patency and reduce inflammation while conforming to the sinus ostia (openings) through mechanical support and steroid delivery where needed to optimize sinus surgery outcomes.
